Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
a. Abemaciclib (Verzenios) + aromatase inhibitor *
b. Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
c. Alpelisib (Piqray) + Fulvestrant (Faslodex)
d. Atezolizumab (Tecentriq)**
e. Bevacizumab (Avastin)
f. Eribulin (Halaven)
g. Everolimus (Afinitor) + Exemestane
h. Fulvestrant (Faslodex) as a single agent
i. Gemcitabine + paclitaxel
j. Herceptin (Trastuzumab) + paclitaxel
k. Herceptin (Trastuzumab) as a single agent
l. Lapatinib (Tyverb)
m. Neratinib (Nerlynx)
n. Olaparib (Lynparza)
o. Palbociclib (Ibrance) + aromatase inhibitor*
p. Palbociclib (Ibrance) + Fulvestrant (Faslodex)
q. Pertuzumab (Perjeta) + trastuzumab + docetaxel
r. Ribociclib (Kisqali) + aromatase inhibitor*
s. Ribociclib (Kisqali) + Fulvestrant (Faslodex)
t. Talazoparib (Talzenna)
u. Trastuzumab emtansine (Kadcyla)
v. Other active systemic anti-cancer therapy **
*aromatase inhibitor e.g. Anastrozole, Exemestane or Letrozole
**e.g. docetaxel, vinorelbine or capecitabine as a single agent
Q2. For the above patients, how many of these received their first ever dose for each product line?
